← 返回

K(+) 通道抑制对 CAR-T 细胞靶细胞杀伤潜能的影响

英文原题:Inhibition of K(+) Channels Affects the Target Cell Killing Potential of CAR T Cells.

查看英文原题

Inhibition of K(+) Channels Affects the Target Cell Killing Potential of CAR T Cells.

PubMed 2024/11/06(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞离子通道(Kv1.3、KCa3.1和CRAC)通过调节Ca2+依赖通路,参与T细胞活化和效应功能的调控。表达嵌合抗原受体的T细胞(CAR-T)在抗肿瘤治疗中发挥显著作用,尤其适用于化疗耐药的血液肿瘤,但实体瘤治疗仍有诸多挑战。

本研究评估CAR-T 细胞中离子通道的表达和作用。研究发现,与未转导对照细胞相比,HER2特异性CAR-T 细胞的KCa3.1电导增强,在CD8+细胞群体中尤为明显(CD4+细胞也有升高)。相反,Kv1.3在所有细胞类型(CD4+、CD8+、CAR及未转导细胞)中的表达水平相同。单细胞Ca2+成像显示,毒胡萝卜素诱导的、经CRAC通道介导的储存操纵性钙内流(SOCE)在CD8+ CAR-T 细胞中受到抑制,而CD4+及CD8+未转导细胞中未见此现象。为解析Kv1.3和KCa3.1的功能作用,研究使用特异性拮抗剂(Kv1.3:Vm24;KCa3.1:TRAM-34);阻断任一通道均可增强CD8+ CAR-T 细胞清除靶细胞的能力。这些结果提示,离子通道可作为CAR-T 免疫治疗优化的靶点。

展开英文摘要原文

Ion channels of T cells (Kv1. 3, KCa3. 1, and CRAC) participate in the regulation of activation and effector functions via modulation of the Ca 2+ -dependent pathway. T cells expressing chimeric antigen receptors (CAR T cells) showed a remarkable role in anti-tumor therapy, especially in the treatment of chemotherapy-resistant liquid cancers. Nevertheless, many challenges remain to be overcome to improve the treatment for solid tumors. In this study, we assessed the expression and role of ion channels in CAR T cells.

We found that HER2-specific CAR T cells had higher KCa3. 1 conductance compared to the non-transduced (NT, control) cells, which was more prominent in the CD8 + population (CD4 + cell also showed elevation). Conversely, the Kv1. 3 expression level was the same for all cell types (CD4 + , CD8 + , CAR, and NT). Single-cell Ca 2+ imaging revealed that thapsigargin-induced SOCE via CRAC is suppressed in CD8 + CAR T cells, unlike for CD4 + and CD8 + NT cells.

To dissect the functional role of Kv1. 3 and KCa3. 1, we used specific antagonists (Kv1. 3: Vm24; KCa3. 1: TRAM-34): the target cell elimination capacity of the CD8 + CAR T cells was improved either by blocking KCa3. 1 or Kv1. 3. These results imply that ion channels could be a target in CAR T cell immunotherapy elaboration.

论文信息

作者
Medyouni G、Vörös O、Jusztus V、Panyi G、Vereb G、Szöőr Á、Hajdu P
单位
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.Hungary
期刊
Cancers2024 Nov 6
原文标识
PubMed 39594705 · DOI 10.3390/cancers16223750